Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.